← NewsAll
Canada news is currently paused for latest updates. We'll resume retrieval when enough requests come in.
Biogen Receives European Commission Approval for High Dose SPINRAZA
Summary
The European Commission approved a high dose regimen of SPINRAZA (nusinersen), Biogen announced on January 12, 2026.
Content
Biogen announced that the European Commission has approved a high dose regimen of SPINRAZA (nusinersen) for spinal muscular atrophy. The announcement appeared as a company news release dated January 12, 2026. SPINRAZA is marketed by Biogen under the generic name nusinersen. The release contains standard forward-looking language that outlines risks and uncertainties related to drug development and commercialization.
Key points:
- The European Commission approved a high dose regimen of SPINRAZA (nusinersen).
- Biogen published the announcement on January 12, 2026.
- The company’s news release includes forward-looking statements about potential benefits, risks, and regulatory or commercial outcomes.
- Those forward-looking statements are described as subject to uncertainties and not guarantees of future results.
Summary:
The approval is a regulatory decision affecting a higher-dose SPINRAZA regimen in the European Union and is presented by Biogen alongside cautionary forward-looking language. Undetermined at this time.
